Defunct Company
Total Trials
8
As Lead Sponsor
3
As Collaborator
5
Total Enrollment
309
NCT00077493
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Phase: Phase 1
Role: Collaborator
Start: Jan 31, 2004
Completion: Oct 31, 2008
NCT00587457
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
Start: Mar 7, 2007
Completion: Apr 7, 2008
NCT00457860
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Role: Lead Sponsor
Start: Mar 31, 2007
Completion: Not specified
NCT00462189
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Start: Apr 30, 2007
NCT00586924
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
Start: May 10, 2007
Completion: May 6, 2015
NCT00515892
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Start: Aug 31, 2007
NCT00640016
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
Phase: Phase 2
Start: Jan 31, 2008
Completion: Jul 31, 2008